论文部分内容阅读
肝细胞癌（HCC）是世界上最常见的恶性肿瘤之一，传统的手术及化疗效果局限。多酶抑制剂索拉非尼在HCC的Ⅲ期临床试验中证明对晚期肝癌有效，开创了肝癌治疗新领域。近年来，索拉非尼联合其他方法治疗HCC的研究正在世界各地开展，并取得令人鼓舞的结果。总结了索拉非尼联合肝移植、射频消融术及肝动脉化疗栓塞术治疗肝癌的研究进展，认为索拉非尼与其他抗肝癌治疗的综合运用，有望成为肝癌靶向治疗的新途径。“,”Hepatocellular carcinoma (HCC)is one of the most common malignant tumors worldwide,and traditional surgery and chemother-apy provide limited benefit.Sorafenib,a multikinase inhibitor,was proved effective for advanced HCC in phase III clinical trial,which was a breakthrough in the treatment of HCC.In recent years,the studies on sorafenib combined with other therapies in the treatment of HCC have been conducted around the world,and inspiring results have been seen.The research advances in sorafenib combined with orthotopic liver transplantation,radiofrequency ablation,and transarterial chemoembolization in the treatment of HCC are summarized.It is thought that sor-afenib combined with other anticancer therapies is expected to become a new approach of targeted therapy of HCC.